Daily Stock List
Healthcare Corporation of America (HCCA)
Today we are reporting on Healthcare Corporation of America (HCCA), here at the QualityStocks Daily Newsletter.
Healthcare Corporation of America (HCCA) focuses on reducing prescription drug costs for clients while improving the quality of care for their members. The Company’s subsidiary, HCCA, is a Pharmacy Benefit Manager, or PBM. HCCA administers prescription drug benefits programs for employers who contract with HCCA directly to provide this component of healthcare benefits to their employees. HCCA lists on the OTCQB. The Company has their headquarters in Denville, New Jersey.
In addition, HCCA is the PBM for healthcare management companies who partner with HCCA to provide prescription drug benefits along with their core offering, other health benefits products, to their clients. By way of their PBM subsidiary, Prescription Corporation of America (PCA), HCCA administers prescription drug benefit programs for employers. These employers range from commercial clients of diverse sizes and industries to business associations and trade groups, and local government entities, labor unions, charitable and non-profit organizations, and third-party administrators of self-insured benefit plans.
Through their 340Basics subsidiary, HCCA provides software and services to help Covered Entities manage all processes related to the Federal 340B Drug Discount Program. This includes registration, compliance, audit, claims processing, and access to pharmacies. HCCA’s newly formed subsidiary, Morris Consulting Services (MCS) will work with organizations employing up-to-date data and analytics to assess where costs can be reduced in prescription-drug plans.
In January 2014, HCCA announced the appointment by the Board of Directors of Ms. Natasha Giordano to succeed Mr. Gary Sekulski as Chief Executive Officer (CEO), which was effective January 3, 2014. In addition, Ms. Giordano was elected a Director of the Board of Directors. The Company also announced the appointment of Yaron Eitan, as their new Chairman of the Board of Directors, succeeding Mr. Sekulski. Mr. Sekulski will continue to assist HCCA with their business development activities.
Ms. Giordano has more than 20 years of experience in different leadership positions in the healthcare industry. She served as the CEO, President and Director of Xanodyne Pharmaceuticals, Inc. from May 2010 to August 2012 and Chief Operating Officer since 2009.
Healthcare Corporation of America (HCCA), closed Wednesday's trading session at $0.25, up 150.00%, on 296,580 volume with 38 trades. The average volume for the last 60 days is 3,075 and the stock's 52-week low/high is $0.10/$6.00.
National Holdings Corp. (NHLD)
Wall Street Resources reported on National Holdings Corp. (NHLD), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.
Founded in 1947, National Holdings Corp. is a full-service investment banking and asset management firm. The Company is a foremost Independent Advisor and Broker services company. National Holdings has more than 1,100 Independent advisors, brokers, traders and sales associates. The Company has corporate head offices in New York and Florida. National Holdings’ shares trade on the OTC Bulletin Board.
National Holdings operates through five subsidiaries. These are National Securities Corp., vFinance Investments, Inc., National Insurance Corp. and National Asset Management, Inc. and Gilman Ciocia, Inc.
National Securities and vFinance Investments are broker-dealers registered with the Securities and Exchange Commission (SEC), and members of Financial Industry Regulatory Authority (FINRA) and Securities Investor Protection Corporation (SIPC). National Securities and vFinance are also members of the NFA. National Asset Management is a federally-registered investment advisor. National Insurance provides a full spectrum of fixed insurance products to their clients.
National Holdings provides a selection of services to corporations, institutional investors, and high-net-worth clients. These include independent retail brokerage and advisory services, investment banking, institutional sales and trading and equity research, financial planning, and market making. Additionally, services provided include tax preparation, insurance and annuities.
Recently, National Holdings announced that Mr. John R. Benda joined the Company’s broker-dealer subsidiary, National Securities, as a Senior Equity Research Analyst, covering REITs (Real Estate Investment Trusts) and other real estate related securities. In the new role, Mr. Benda is based in New York. Mr. Benda joins National Securities from Susquehanna International Group. At Susquehanna International he worked in equity research and covered homebuilders, mortgage insurers and single-family rental REITs since 2010.
Last month, ZBB Energy Corp. (ZBB) announced that they completed their previously announced underwritten public offering of common stock at a price to the public of $2.25 per share. ZBB announced the successful completion of the public offering of common stock including full exercise of over allotment. National Securities, the wholly owned subsidiary of National Holdings, acted as sole book-running manager for the offering.
National Holdings Corp. (NHLD), closed Wednesday's trading session at $0.49, down 3.92%, on 282,208 volume with 40 trades. The average volume for the last 60 days is 292,872 and the stock's 52-week low/high is $0.18/$0.60.
Liberty Coal Energy Corp. (LBTG)
Greenbackers reported previously on Liberty Coal Energy Corp. (LBTG), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.
Founded in 2007, Liberty Coal Energy Corp. is an energy resource development and production company. Their principal business focus is to acquire and develop advanced coal properties in North America. The Company has current projects based in North Western Louisiana and Kentucky. Liberty’s principal operating plan is to develop low risk, high yield, and under-developed oil reserves employing the most current technology available.
Liberty Coal Energy lists on the OTC Markets’ OTCQB and the Company is based in Carlsbad, California. They were previously known as ESL Teachers, Inc. They changed their name to Liberty Coal Energy Corp. in March of 2010.
Liberty has entered an acquisition and production program in Louisiana and Northeast Texas. The Company’s current holding is the Gamm lease in Caddo Parrish, Northwest Louisiana. The Gamm lease contains 11 shallow wells - 1,500 to 1,700 feet approximately. These wells were drilled and developed over more than 20 years between the late 1940s and the 1970s.
In addition, Liberty Coal Energy is currently developing a coal project in Owsley County, Kentucky. The Owsley property covers approximately 1,000 acres. It has 3,600,000 tons of coal recoverable by surface and high wall (auger) methods. There are underground reserves in place which are not currently being considered for production. The Owsley project has a permit completed and technically approved by the Kentucky Department of Natural Resources for the first 80 acre phase.
This past January, Liberty Coal Energy announced the resignation of President, Mr. Edwin G. Morrow and the appointment of CFO Mr. Robert T. Malasek to the position of Interim President and CEO.
Liberty Coal accepted the resignation of Edwin G. Morrow and the appointment of CFO Robert T. Malasek to the position of Interim President and CEO on January 29, 2014. Mr. Morrow served as Liberty's President since April 2010. He will continue to serve on the Company's Board of Directors and as Liberty’s Head of Geology. Mr. Malasek joined Liberty in April 2011. The restructuring is intended at creating a more efficient operation to aid Liberty’s progress in implementing their revised Business Plan.
Liberty Coal Energy Corp. (LBTG), closed Wednesday's trading session at $0.001, up 11.11%, on 120,772,284 volume with 140 trades. The average volume for the last 60 days is 69,862,212 and the stock's 52-week low/high is $0.0001/$0.06.
Cannabis-Rx, Inc. (CANA)
TradingAuthority Daily, StreetAuthority Daily, and TopStockAnalysts reported previously on Cannabis-Rx, Inc. (CANA), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.
OTCQB-listed Cannabis-Rx, Inc. is a US real estate development company seeking to grow their portfolio with long-term strategic investments within the regulated cannabis industry. The Company is focusing on funding the licensed cannabis industry by providing cannabis-based businesses with capital and real estate opportunities to enhance operations and facilitate growth. In addition, Cannabis-Rx provides regulatory compliance, license application and grow operation consulting services to licensed cannabis growers and operators.
The Company formerly went by the name Longview Real Estate, Inc. They changed their name to Cannabis-Rx, Inc. in January 2014. Founded in 2011, Cannabis-Rx has their head office in Scottsdale, Arizona. Mr. Llorn Kylo, an experienced real estate executive, investor and developer, founded Cannabis-Rx. He is the Chief Executive Officer of the Company.
Cannabis-Rx invests in light industrial and commercial properties suited for the needs of growers, suppliers or distributors of licensed cannabis and ancillary type products. The Company will also consider additional investment opportunities in the licensed cannabis industry. This ranges from retail and construction to nutrient lines and logistics, and providing start-up or operating capital to businesses that meet certain criteria.
Cannabis-Rx purchases light industrial and commercial real estate properties in the 10,000 to 100,000 sq. ft. range. Their intention is to lease them to licensed marijuana businesses operating in Colorado and Washington, and also other states that permit the use and/or growth of medicinal marijuana. The Company is willing to renovate these spaces based on the requirements of the business, and include these additional costs into their lease. Cannabis-Rx’s industry leading terms offer 24-48 month tenant purchase options. This provides flexibility for the tenant long-term while lowering capital expenditure requirements.
The Company has completed a $12,000,000 USD financing. Their plan is to deploy capital in light industrial and commercial properties suited for the needs of growers, suppliers or distributors of licensed marijuana and ancillary type products.
Cannabis-Rx, Inc. (CANA), closed Wednesday's trading session at $0.98, up 1.02%, on 77,910 volume with 67 trades. The average volume for the last 60 days is 21,628 and the stock's 52-week low/high is $0.1251/$7.20.
Capstone Companies, Inc. (CAPC)
Today we are reporting on Capstone Companies, Inc. (CAPC), here at the QualityStocks Daily Newsletter.
Listed on the OTCQB, Capstone Companies, Inc. is a holding company based in Deerfield Beach, Florida. They engage, through their wholly-owned subsidiaries, Capstone Industries, Inc., Capstone Lighting Technologies, LLC, and Capstone International HK, Ltd., in the development, manufacturing, logistics, and distribution of consumer and institutional products to accounts throughout North America and in global markets. The Company previously went by the name CHDT Corp. They changed their corporate name to Capstone Companies, Inc. in June of 2012.
Capstone Companies is a leader in the design and manufacture of specialty power failure lighting solutions. In addition, the Company is an innovator of consumer safety and security products for the hospitality, retail, as well as institutional channels. Their products, by way of Capstone Industries, includes book lights, e-reader lights, motion sensor lights, plug-in sconces, tasklights, door security monitors, headlights, nightlights, and power failure lights.
The powering of the Company’s Power Failure solutions are by advanced technology rechargeable batteries and LED bulbs, which never need replacing. The products utilize a stylish industrial design approach. Capstone’s signature power failure feature is engineered with proprietary circuitry; it allows their products to turn on when the power goes out.
Capstone Companies announced in August 2013 that they successfully developed the 2-in-1 10 LED Wall Plate. This is the most recent addition to their power failure lighting solutions product group. The 2-in-1 10 LED Wall Plate provides dual functionality as a nightlight and a power failure solution in the form of a wall plate cover. This unique design allows for the added safety of emergency power failure lighting solutions with a sleek and cleaner look.
In February of this year, Capstone Companies announced that their wholly-owned subsidiary, Capstone Lighting Technologies, was assigned the power failure technology patent application filed on January 3, 2014, by inventors Neil Singer, PhD, Ken Pasch, PhD and John Granada, from AC Kinetics and Stewart Wallach, Chief Executive Officer of Capstone Companies. The proprietary technical attributes of the technology enables unique power failure detection, switch controlled properties, and thermal protection.
Capstone Companies, Inc. (CAPC), closed Wednesday's trading session at $0.0285, up 5.56%, on 742,864 volume with 39 trades. The average volume for the last 60 days is 339,174 and the stock's 52-week low/high is $0.0025/$0.027.
Pan Global Corp. (PGLO)
The QualityStocks Daily Newsletter would like to spotlight Pan Global Corp. (PGLO). Today, Pan Global Corp. closed trading at $0.175, up 24.91%, on 796,570 volume with 126 trades. The stock’s average daily volume over the past 60 days is 306,614, and its 52-week low/high is $0.09/$3.50.
Pan Global Corp. today announced the 2nd installment in a five-part series of press releases intended to provide its current and prospective shareholders with the Company's analysis of its opportunity in India's green energy industry plus additional details about its small-hydro plant acquisitions. Management is confident that the path they have chosen is the right one and reaffirmed that they are committed to the long term goal of building shareholder value, and that they are fully intent on continuing to increase the company's equity interest in RYEL under the acquisition agreement, designed to place a 5.7MW small-hydro project in northern India under PGLO's control.
Pan Global Corp. (PGLO) is focused on building the world’s green economy by developing, building, owning, and operating the necessary infrastructure. Current opportunities are currently concentrated on developing projects in India, specifically in the areas of hydro-power generation, solar PV, geo-thermal, sustainable agriculture, and green construction.
The India growth story is frequently compared to China, which has sustained above-average annual growth for three decades, whereas India’s take-off growth began at a later stage. During the last decade, India’s growth has averaged approximately 8% per year. India is poised for high GDP growth that will be sustained for decades to come.
Within the Indian market there are available various government-backed incentives programs, including those which provide direct tariff subsidies as well as market-based tariff support through renewable energy credits. Assessing project viability on a case by case basis, Pan Global seeks to invest in projects both as owner-developers and/or as partners with other developers.
Pan Global’s business strategy is an extension of the company’s commitment to improve human well-being and social equity, while significantly reducing environmental risks and ecological scarcities. By developing a series of highly environmentally sustainable and high ROI projects, Pan Global aims to accelerate business growth. Disclaimer
Pan Global Corp. Company Blog
Pan Global Corp. News:
Pan Global, Corp. Provides Part B of Analysis Series for Shareholders -- Industry Reports Indicate Small-Hydro Has Big Potential
Pan Global, Corp. Launches Analysis Series for Shareholders - Part A - "India's Renewable Energy Potential Remains Untapped"
Pan Global, Corp. Commences Site Visits and Inspections of First Small-Hydro Plant Acquisition in Advance of Anticipated Power Grid Connection
Global Payout, Inc. (GOHE)
The QualityStocks Daily Newsletter would like to spotlight Global Payout, Inc. (GOHE). Today, Global Payout, Inc. closed trading at $0.22, even with yesterday's close, on 199,223 volume with 28 trades. The stock’s average daily volume over the past 60 days is 64,950, and its 52-week low/high is $0.03/$0.41.
Global Payout, Inc. announce the availability of a "state of the art" tax refund platform designed for EROs (Electronic Return Originators) to offer instant issuance debit cards to their tax return clients. The platform combines both Global Payout's prepaid debit card offering with the CPG eWallet (Consolidated Payment Gateway Electronic Wallet) technology enabling tax preparers to "instant issue" debit cards that receive direct deposit of refunds from the IRS and US Treasury.
Global Payout, Inc. (GOHE) specializes in customized payment solutions for businesses and organizations worldwide. The company’s global network of banks and processing partners enable companies and organizations to efficiently deploy a customized payment solution configured specifically for each client. From solving a single payment issue to meeting an entire global payment requirement, Global Payout in conjunction with its partners delivers modular payment solutions.
Global Payout has a product line of prepaid "off the shelf" products that can be utilized or Global Payout can customize payment solutions for qualified businesses. By coupling its network of international banks and third-party processing relationships with an innovative payment platform, Global Payout enables organizations to "plug into" an efficient and cost effective method of paying employees, contractors, investors, and commissioned agents wherever they might be located in the world.
Global Payout began operations as a business to business provider of pre-paid debit cards for payroll and general spend programs. The company then launched a Prepaid Discover® card to meet the demand of its business clients in the United States. As a result of these efforts and with the input of their client base, Global Payout then greatly extended its reach by developing a new proprietary “payment platform” which enables companies and organizations to make necessary payments in every country a company does business. Clients can now make international payments without the need to establish banking relationships in each and every country they do business. Businesses now have an efficient, compliant and simplified system to make their all necessary international payments using Global Payout’s proprietary payment platform.
Global Payout delivers dependable and secure global payment solutions for companies worldwide. This relieves clients of burdensome and time consuming efforts to establish banking relationships everywhere they do business. The company’s “consolidated payment gateway” product can be configured specifically to the needs of each client within a short period of time. Global Payout is led by a management team comprised of pioneers in domestic and international payment delivery solutions. The company is well positioned to leverage their long standing international financial relationships to expand their services and global reach. Even during this expansion, Global Payout remains committed to serving domestic and international clients and providing them with customized one-stop solutions that address each client’s specific payment needs. Disclaimer
Global Payout, Inc. Company Blog
Global Payout, Inc. News:
Global Payout & New Payment Solutions Unveil Innovative New Tax Refund Payment Platform Creating Another New Market Niche
Brazil Opens Major Market Opportunity For Global Payout
Payment Platform Achieves Major Expansion To Worldwide Status
International Stem Cell Corp. (ISCO)
The QualityStocks Daily Newsletter would like to spotlight International Stem Cell Corp. (ISCO). Today, International Stem Cell Corp. closed trading at $0.192, up 6.55%, on 722,326 volume with 100 trades. The stock’s average daily volume over the past 60 days is 674,932, and its 52-week low/high is $0.13/$0.34.
International Stem Cell Corp. (ISCO) specializes in the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. The company was first to perfect the natural phenomenon of parthenogenesis, which utilizes unfertilized human eggs to create hpSCs. These stem cells, created in a particular form called HLA homozygous, can be immune-matched to millions of people regardless of sex or racial background, with minimal expectation of immune rejection after transplantation.
hpSCs are as pluripotent as embryonic stem cells (ESCs) and have significant therapeutic potential but their creation does not involve the destruction of a viable human embryo – thus sidestepping the controversy and ethical dilemmas associated with the use of human embryonic stem cells. Different from induced pluripotent stem cells (iPSs), hpSCs do not involve manipulation of gene expression back to a less differentiated stage – a practice that may become a safety or regulatory obstacle in clinical applications.
A relatively small number of hpSC lines can offer the potential of producing the first true stem cell bank, UniStemCell, which ISCO intends to create as a means of serving populations across the globe. The company's scientists are currently focused on using hpSC to treat severe diseases of the eye, nervous system, and liver, for which cell therapy has been clinically proven but is limited due to the unavailability of safe human cells.
In addition to its therapeutic focus, ISCO also provides two revenue streams. Firstly through its subsidiary Lifeline Cell Technology, specialized cells and growth media for biological research around the world, and secondly its subsidiary Lifeline Skin Care, the company manufactures and sells anti-aging skincare products utilizing an extract from the hpSC and by leveraging the latest discoveries in the fields of stem cell biology, nanotechnology, and skin cream formulation technology. Disclaimer
International Stem Cell Corp. Company Blog
International Stem Cell Corp. News:
Lifeline Skin Care Expands Into Latin America's Second Largest Market
International Stem Cell Corporation Announces 2013 Fourth Quarter and Year-End Results
International Stem Cell Corporation to Host Full-Year 2013 Business Update and Financial Results Conference Call Wednesday, March 19, 2014
Infinite Group, Inc. (IMCI)
The QualityStocks Daily Newsletter would like to spotlight Infinite Group, Inc. (IMCI). Today, Infinite Group, Inc. closed trading at $0.092, even for the day, on 550 volume with 2 trades. The stock’s average daily volume over the past 60 days is 5,962, and its 52-week low/high is $0.05/$0.20.
Infinite Group, Inc. (IMCI) professionals plan, integrate, manage and support complete IT solutions for customers in small to medium-sized businesses, government agencies and large commercial enterprises. Dedicated to quality and customer service, the company’s team of over 80 IT specialists is experienced in their individual fields and maintains the latest certifications. Infinite Group also partners with industry leaders such as VMware, HP, Microsoft, Cisco, and Dell to ensure its customers receive the best combination of products and services designed for their specific needs.
The company’s scalable solutions cover the entire IT chain, including consulting and project management, data storage and recovery solutions, IT security, managed services, and complete IT system development. Providing customers a single point of contact for all their IT needs, Infinite Group helps companies focus on their core business by improving IT efficiencies, reducing capital expenditures, and enjoying significant savings on operational costs.
Based in the Rochester, New York area, the company leverages its deep roots in technology to be one of today’s premier IT service and support suppliers. The company’s IT professionals provide on-site support to customers around the world and serve some of the premiere businesses and government organizations in the United States and worldwide including the U.S. Post Office, PepsiCo, Inc., the State of Mississippi, Home Depot, NASA, Pricewaterhouse Coopers, the Florida Department of Financial Services, the U.S. Air Force, Navy, Army, and others. Personnel are located throughout the U.S. including Colorado Springs, Springfield and Vienna, Virginia and Washington, D.C. for added government support.
The IT services industry generates $500 billion in annual revenues and continues to grow as businesses progressively rely on technology to maintain operations and increase efficiency. With decades of experience and technical knowledge, and guided by the highest governance and business conduct guidelines, Infinite Group’s leadership team meets current and future business demands with expertise and effectiveness. Disclaimer
Infinite Group, Inc.Company Blog
Infinite Group, Inc.News:
Cybersecurity on Infinite Group, Inc.'s Radar With New Hire
Infinite Group, Inc. CEO Featured in Exclusive QualityStocks Interview
Infinite Group, Inc. Adds Donald Reeve to Board
VistaGen Therapeutics, Inc. (VSTA)
The QualityStocks Daily Newsletter would like to spotlight VistaGen Therapeutics, Inc. (VSTA). Today, VistaGen Therapeutics, Inc. closed trading at $0.4598, even for the day. The stock’s average daily volume over the past 60 days is 3,893, and its 52-week low/high is $0.25/$0.90.
VistaGen Therapeutics, Inc. (VSTA) is a biotechnology company applying stem cell technology for drug rescue and cell therapy. Drug rescue combines human stem cell technology with modern medicinal chemistry to generate new chemical variants ("drug rescue variants") of once-promising drug candidates that have been discontinued during late-stage preclinical development due to heart or liver safety concerns. VistaGen also focuses on cell therapy, or regenerative medicine, which includes repairing, replacing or restoring damaged tissues or organs.
VistaGen's versatile stem cell technology platform, Human Clinical Trials in a Test Tube™, has been developed to provide clinically relevant predictions of potential heart and liver toxicity of promising new drug candidates long before they are ever tested on humans.
By more closely approximating human biology than conventional animal studies and other nonclinical techniques and technologies currently used in drug development, VistaGen's human stem cell-based bioassay systems can improve the predictability of the drug development cycle and lower the cost of new drug research and development by identifying product failures earlier in the cost curve. According to the Food and Drug Administration even only a ten percent improvement in predicting failure before clinical trials could save $100 million in development costs, which savings ultimately could be passed on to patients.
Using mature human heart cells produced from stem cells, VistaGen has developed and internally validated CardioSafe 3D™, a novel three-dimensional (3D) bioassay system for predicting the in vivo cardiac effects of new drug candidates before they are tested in humans. VistaGen is now focused on using CardioSafe 3D™ to generate up to two new, safer small molecule drug rescue variants every twelve to eighteen months. VistaGen anticipates that these drug rescue variants will be modified versions of once-promising new drug candidates that have been discontinued by pharmaceutical companies and academic research institutions because of heart toxicity concerns, despite substantial prior investment and positive efficacy data demonstrating their potential therapeutic and commercial benefits. In most cases, VistaGen plans to license or sell its new, safer drug rescue variants in strategic partnering arrangements with global pharmaceutical companies, arrangements providing VistaGen with both near term and downstream milestone payments and economic participation rights but without future development cost obligations.
AV-101, VistaGen's lead small molecule prodrug candidate has successfully completed Phase I clinical development in the U.S. for treatment of neuropathic pain, a serious and chronic condition affecting millions of people worldwide, depression, and other neurological diseases and conditions. To date, the U.S. National Institutes of Health (NIH) has awarded VistaGen over $8.75 million for development of AV-101. Management anticipates strategically out-licensing AV-101 to a development and marketing partner in 2013.
Neuropathic pain affects approximately 1.8 million people in the U.S. alone. Although the current active AV-101 IND is for the treatment of neuropathic pain, VistaGen's development plan and regulatory strategy for AV-101 has been designed to allow its Phase 1 safety studies to support Phase 2 development for depression, epilepsy, Huntington's Disease and Parkinson's disease, indications for which there is now supporting preclinical efficacy data. To date, VistaGen has been awarded over $8.5 million from the U.S. National Institutes of Health (NIH) for development of AV-101.
VistaGen is also developing LiverSafe 3D™, a novel predictive liver toxicity and drug metabolism bioassay system for drug rescue applications. In parallel with drug rescue activities, the Company is funding early-stage nonclinical studies focused on potential cell therapy applications of its Human Clinical Trials in a Test Tube™ platform. Disclaimer
VistaGen Therapeutics, Inc. Company Blog
VistaGen Therapeutics, Inc. News:
VistaGen Provides Update on $36 Million Strategic Financing Agreement
VistaGen Therapeutics Presents CardioSafe 3D and LiverSafe 3D Developments at International Society of Stem Cell Research's 11th Annual Meeting
VistaGen Therapeutics and Duke University Publish Results on Production of Functional 3D Human Heart Tissue
Today's Top 3
The QualityStocks Public Company Sponsor News
- Get profiles for new featured companies at clients.qualitystocks.net
- Armco Metals Holdings, Inc. (AMCO) and Midland Resources Enter Into Steel Scrap Supply Agreement
- Big Tree Group, Inc. (BIGG) to Exhibit at Toy Fair 2014 in New York City at the Jacob K. Javitz Convention Center
- China Logistics Group, Inc. (CHLO) Pursues Strategic Acquisition Candidates
- Consorteum Holdings, Inc. (CSRH) and The Alternative Initiate New Brand Development Project
- eCrypt Technologies, Inc. (ECRY) Appoints Former Microsoft Engineer to Advisory Board
- Global Payout, Inc. (GOHE) & New Payment Solutions Unveil Innovative New Tax Refund Payment Platform Creating Another New Market Niche
- GlobalWise Investments, Inc. (GWIV) Investments Announces Results for Fiscal Year 2013
- Great Plains Holdings, Inc. (GTPH) President to Exhibit and Present at the Las Vegas MoneyShow
- Infinite Group, Inc. (IMCI) Cybersecurity In Focus At IMCI With New Hire
- Innocent, Inc. (INCT) Announces Letter to Shareholders
- International Stem Cell Corp. (ISCO) Lifeline Skin Care Expands Into Latin America's Second Largest Market
- Kallo, Inc. (KALO) Update on US $200,000,925.00 Supply Contract for Kallo MobileCare and RuralCare in Guinea
- Mabwe Minerals Inc. (MBMI) Raptor Resources Holdings Completes Expansion of the Dodge Mine Mountain Range
- NeuroMama, Ltd. (NERO) CES Event Showcasing Intelligent Search Engine, Online Retail Platform and Advertising Opportunities, Reception Act Performer Fall and Serious Injuries Documented
- Nexus Enterprise Solutions, Inc. (NXES) A Letter to Shareholders from Nexus CEO James Bayardelle
- NutraNomics, Inc. (NNRX) Discusses Long-Term Global Expansion Strategy with UNO International Corp.
- Pan Global, Corp. (PGLO) Provides Part B of Analysis Series for Shareholders -- Industry Reports Indicate Small-Hydro Has Big Potential
- P2 Solar, Inc. (PTOS) Update on Langley Rooftop Project
- Raptor Resources Holdings Inc. (RRHI) Acquires the Derbyshire Stone Quarry
- Speedemissions, Inc. (SPMI) Reports Year End 2013 Results
- Start Scientific, Inc. (STSC) is “One to Watch”
- Victory Energy Corp. (VYEY) Engages Euro Pacific Capital
- VistaGen Therapeutics, Inc. (VSTA) Provides Update on $36 Million Strategic Financing Agreement
- Well Power Inc. (WPWR) Closes First Round Of Funding